N-tert-Butyl-2,2-dimethylpropansulfonsaeureamid | 78076-98-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: N-tert-Butyl-2,2-dimethylpropansulfonsaeureamid
• 英文别名: N-tert-butyl-2,2-dimethylpropane-1-sulfonamide
• CAS: 78076-98-9
• 化学式: C₉H₂₁NO₂S
• 分子量: 207.337
• InChiKey: MSNPVJIFTPDXOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-tert-Butyl-2,2-dimethylpropansulfonsaeureamid 在 次氯酸叔丁酯 作用下， 以 四氯化碳 为溶剂， 反应 24.0h， 以87%的产率得到N-tert-Butyl-N-chlor-2,2-dimethylpropansulfonsaeureamid
  参考文献：
  名称：

  Quast, Helmut; Kees, Frieder, Chemische Berichte, 1981, vol. 114, # 2, p. 774 - 786

  摘要：

  DOI：
• 作为产物：
  描述：

  叔丁胺 、 2,2-二甲基丙烷-1-磺酰氯 以 乙醚 为溶剂， 反应 0.25h， 以81%的产率得到N-tert-Butyl-2,2-dimethylpropansulfonsaeureamid
  参考文献：
  名称：

  Quast, Helmut; Kees, Frieder, Chemische Berichte, 1981, vol. 114, # 2, p. 774 - 786

  摘要：

  DOI：

文献信息

• SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
  申请人：Bignan Gilles

  公开号：US20110294780A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性腰部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，遗传性骨发育不全，骨溶解性骨转移，软骨软化症，骨质疏松症，帕金森病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的方法。
• QUAST H.; KEES F., CHEM. BER., 1981, 114, NO 2, 774-786
  作者：QUAST H.、 KEES F.

  DOI：——

  日期：——
• Bifunctional macrolide heterocyclic compounds and methods of making and using the same
  申请人：Oyelere K. Adegboyega

  公开号：US20070149463A1

  公开（公告）日：2007-06-28

  The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of bifunctional compounds useful as therapeutic agents. These compounds have both a macrolide ring and at least one heterocyclic moiety. The present invention further relates to processes for the preparation of such compounds, to intermediates useful in their preparation, to the use of the compounds as therapeutic agents, and to pharmaceuticals compositions containing them.
• US8796256B2
  申请人：——

  公开号：US8796256B2

  公开（公告）日：2014-08-05
• Quast, Helmut; Kees, Frieder, Chemische Berichte, 1981, vol. 114, # 2, p. 774 - 786
  作者：Quast, Helmut、Kees, Frieder

  DOI：——

  日期：——